Results 151 to 160 of about 4,022 (166)

Cefiderocol (S-649266)

2017
Cefiderocol (S-649266) is a novel siderophore cephalosporin, initially developed jointly by Shionogi Inc. and Glaxo Smith Kline. From November 9, 2015, further development was by Shio nogi alone. By virtue of in vitro activity against carbapenem- resistant Enterobacteriaceae (CRE), including those producing Klebsiella pneumoniae carbapenemase (KPC ...
openaire   +2 more sources

Cefiderocol/colistin/tigecycline

Reactions Weekly, 2021
openaire   +1 more source

Pharmacokinetic and Pharmacodynamic Profiles of Cefiderocol, a Novel Siderophore Cephalosporin

Clinical Infectious Diseases, 2019
Takayuki Katsube, Roger Echols, Toshihiro Wajima   +2 more
exaly  

Clinical efficacy of cefiderocol-based regimens in patients with carbapenem-resistant Acinetobacter baumannii infections: A systematic review with meta-analysis

International Journal of Antimicrobial Agents
Milo Gatti, Federica Cosentino, Maddalena Giannella   +2 more
exaly  

Global prevalence of cefiderocol non-susceptibility in Enterobacterales, Pseudomonas aeruginosa, Acinetobacter baumannii, and Stenotrophomonas maltophilia: a systematic review and meta-analysis

Clinical Microbiology and Infection
Stamatis Karakonstantis, Evangelos I Kritsotakis   +1 more
exaly  

Cefiderocol/colistin

Reactions Weekly
openaire   +2 more sources

Cefiderocol: Clinical application and emergence of resistance

Drug Resistance Updates
Hong Du
exaly  

Cefiderocol Sulfate Tosylate

2021
openaire   +1 more source

Amikacin/Cefiderocol

Reactions Weekly
openaire   +1 more source

Cefiderocol/Daptomycin

Reactions Weekly
openaire   +2 more sources